TrialThe oncologist2017

Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients.

Sara M Tolaney et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.